Recently, it has also been shown that observing changes in the FREM2 signaling pathway, rather than only the FREM2 expression level, represents a more reliable prognostic glioblastoma biomarker that is comparable to the already established isocitrate dehydrogenase (IDH) biomarker [46]. Here, FREM2 is linked to glioblastoma.